# Assessment of causality association between serum adiponectin levels and the risk of Alzheimer’s disease and Parkinson’s disease: a Mendelian randomization study

**Authors:** Jiali Lin, Langhuan Lei, Qiuyu Liang, Xiaozhi Huang, Yanping Ding, Liuxian Pan, Jianrong Yang, Wei Li

PMC · DOI: 10.3389/fneur.2025.1395798 · Frontiers in Neurology · 2025-04-30

## TL;DR

This study finds no causal link between adiponectin levels and Alzheimer’s or Parkinson’s disease, but suggests a possible connection with lower inflammation.

## Contribution

The study uses Mendelian randomization to assess causality between adiponectin and neurodegenerative diseases for the first time.

## Key findings

- No significant causal association was found between adiponectin levels and Alzheimer’s or Parkinson’s disease.
- Adiponectin levels showed a negative correlation with interleukin 1β, suggesting a potential anti-inflammatory effect.
- Sensitivity analyses confirmed no evidence of pleiotropy, supporting the robustness of the findings.

## Abstract

Until recently, the association between circulating adiponectin (ADPN) levels and the risk of Alzheimer’s disease (AD) and Parkinson’s disease (PD) remained unclear.

We utilized public data from the IEU GWAS database to conduct a two-sample bidirectional Mendelian randomization (MR) analysis and multiple sensitivity analyses. The MR analysis was performed using the aggregated data, with the genetic risk score (GRS) serving as an instrumental variable.

The MR analyses revealed no significant causal association between genetically determined ADPN levels and the risk of AD (ORIVW = 0.852, 95% confidence interval [CI]: 0.586–1.117, p = 0.235) or PD (ORIVW = 0.830, 95% CI: 0.780–1.156, p = 0.606). Conversely, neither AD nor PD demonstrated any causal association with ADPN levels. The GRS approach yielded similar results (p > 0.05). However, it exhibited a negative correlation with interleukin 1β (IL1β, βIVW = −0.31; 95% CI: −0.55 to −0.07, p = 0.011). The Cochrane’s Q test and MR-PRESSO analysis revealed no evidence of pleiotropy.

Our findings provide no evidence to substantiate a causal relationship between ADPN levels and the risk of AD and PD or vice versa. However, elevated levels of ADPN may correlate with lower levels of IL1β.

## Linked entities

- **Diseases:** Alzheimer’s disease (MONDO:0004975), Parkinson’s disease (MONDO:0005180)

## Full-text entities

- **Genes:** IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, ADIPOQ (adiponectin, C1Q and collagen domain containing) [NCBI Gene 9370] {aka ACDC, ACRP30, ADIPQTL1, ADPN, APM-1, APM1}, Il1 (interleukin 1 complex) [NCBI Gene 111343] {aka Il-1}, ADIPOR2 (adiponectin receptor 2) [NCBI Gene 79602] {aka ACDCR2, PAQR2}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, Adipor1 (adiponectin receptor 1) [NCBI Gene 72674] {aka 2810031L11Rik, ACDCR1, CGI-45, Paqr1}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Pparg (peroxisome proliferator activated receptor gamma) [NCBI Gene 19016] {aka Nr1c3, PPAR-gamma, PPAR-gamma2, PPARgamma, PPARgamma2}, App (amyloid beta precursor protein) [NCBI Gene 11820] {aka Abeta, Abpp, Adap, Ag, Cvap, E030013M08Rik}, IFNR (interferon production regulator) [NCBI Gene 3466] {aka IFNGM, IFNGM2}, Pnpla3 (patatin-like phospholipase domain containing 3) [NCBI Gene 116939] {aka Adpn}, Adipoq (adiponectin, C1Q and collagen domain containing) [NCBI Gene 11450] {aka 30kDa, APN, Acdc, Acrp30, Ad, Adid}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** dementia (MESH:D003704), type 2 diabetes (MESH:D003924), PD (MESH:D010300), obese (MESH:D009765), insulin resistance (MESH:D007333), ND (MESH:C537849), MSA-P (MESH:C537381), cardiovascular disease (MESH:D002318), PSP (MESH:D011030), diabetes (MESH:D003920), Neurogenic inflammation (MESH:D020078), AbetaO (MESH:C000718787), atherosclerosis (MESH:D050197), NDs (MESH:D019636), AD (MESH:D000544), metabolic diseases (MESH:D008659), chronic inflammation (MESH:D007249), neuroinflammation (MESH:D000090862), MR (MESH:C562757)
- **Chemicals:** GRSADPN (-), lipid (MESH:D008055), RNS (MESH:D011886)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** rs12977604, rs10451230, Rs12051272, rs12972156, rs601339, rs35265698, rs2980879, rs7964945
- **Cell lines:** Neuro2A — Mus musculus (Mouse), Mouse neuroblastoma, Cancer cell line (CVCL_0470)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12075267/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12075267/full.md

## References

36 references — full list in the complete paper: https://tomesphere.com/paper/PMC12075267/full.md

---
Source: https://tomesphere.com/paper/PMC12075267